Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368444 | 0.98 | HTR6 (0.39) | HTR6 | |
| SCHEMBL20602546 | 0.93 | — | — | |
| SCHEMBL20601919 | 0.93 | — | — | |
| SCHEMBL95184 | 0.93 | — | — | |
| SCHEMBL5408434 | 0.87 | HTR6 (0.32) | HTR6 | |
| SCHEMBL21853899 | 0.84 | KDM4E (0.31) | KDM4EALDH1A1 | |
| SCHEMBL27491967 | 0.84 | HTR6 (0.33) | HTR6 | |
| SCHEMBL8834900 | 0.79 | HTR6 (0.38) | HTR6KDM4EALDH1A1 | |
| SCHEMBL20742608 | 0.73 | — | — | |
| SCHEMBL4977845 | 0.71 | HTR6 (0.38) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | claimed |
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | claimed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | claimed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | claimed |
| WO-2024017227-A1 | SUBSTITUTED FUSED RING CANNABINOID RECEPTOR COMPOUND AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-01-25 | — | — | WO | claimed |
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | claimed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | claimed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | claimed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | claimed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | claimed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | claimed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | HTR6 4685/4885KDM4E 1818/4885ALDH1A1 1801/4885 |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | HTR6 174/4885KDM4E 3237/4885ALDH1A1 1524/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | HTR6 118/4885KDM4E 3404/4885ALDH1A1 1492/4885 |
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | HTR6 931/4885KDM4E 2172/4885ALDH1A1 1675/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | HTR6 51/4885KDM4E 2973/4885ALDH1A1 1430/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | HTR6 1153/4885KDM4E 4328/4885ALDH1A1 740/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | HTR6 931/4885KDM4E 2199/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.